Cetuximab biosimilar - MabionAlternative Names: MabionEGFR
Latest Information Update: 19 Jun 2015
At a glance
- Originator Mabion
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 10 Jun 2015 Mabion plans clinical trial for Cancer in Poland in 2016-2017 (Mabion website, June 2015)